Opendata, web and dolomites

LIFEOMEGA

Innovative highly concentrated Omega 3 food supplement

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIFEOMEGA project word cloud

Explore the words cloud of the LIFEOMEGA project. It provides you a very rough idea of what is the project "LIFEOMEGA" about.

acid    ml    consists    innovative    cardiovascular    cancer    15    normally    uk    concentrated    spain    cosmetic    sachet    permit    commercialization    business    sclerosis    gr    epa    france    treatment    juice    cover    athletes    constituted    mentioned    ip    permits    fewer    emulsion    people    liquids    acids    grams    economical    consisting    fats    competition    11    chemotherapy    feasibility    clinical    necks    minimizing    lifeomega    retinal    patients    million    tgs    suffer    supports    constitute    dilution    utilized    usa    inflammatory    concentration    fatty    risk    psoriasis    maximum    reduce    maintaining    liquid    omega    requirement    market    pharma    life    diseases    quality    anorexia    italy    weight    won    solution    food    soup    nutrition    arthritis    search    asthma    innovation    plan    chronic    supplement    milk    musculature    dosages    regulatory    protecting    emulsions    meeting    ideal    cachexia    receiving    nutritional    form    helps    bottle    joints    dietary    germany    multiple    extra    unfortunately    pro    saturated   

Project "LIFEOMEGA" data sheet

The following table provides information about the project.

Coordinator
SOLUTEX GC SL 

Organization address
address: CTR DE BARAJAS 24 3-4 PARQUE EMPRESARIAL OMEGA EDIFICIO GAMMA
city: ALCOBENDAS MADRID
postcode: 28108
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.solutex.es
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.3.2. (SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SOLUTEX GC SL ES (ALCOBENDAS MADRID) coordinator 50˙000.00

Map

 Project objective

The project aims to develop an innovative food supplement consisting on a high concentrated emulsion of Omega-3 fatty acid EPA. Omega-3 is utilized as a treatment in psoriasis, arthritis, asthma, multiple sclerosis, chronic inflammatory, cancer, high TGs, retinal diseases and cardiovascular failure.

It consists of 15 ml liquid concentration of EPA, minimizing the level of saturated fats. It’s high concentrated -3 grams EPA/ sachet–, so it allows meeting the nutritional requirements in fewer dosages. Similar products in the market are constituted of maximum 1 gr. EPA, in which a higher concentration means higher level of saturated fats. Liquid form permits the dilution in other liquids, as milk, soup, or juice.

These features permit the following applications: 1) Clinical nutrition: most of cancer patients suffer cachexia or anorexia. EPA supports weight management, reduce the pro-inflammatory response and improve quality of life.

2) Dietary supplement: EPA helps maintaining the musculature and protecting the joints, so it is ideal for competition athletes.

Innovation is present in all aspects: application, as the multiple emulsions technology is applied to food products – normally it is applied in cosmetic or pharma-; product, as there are no products in the market offering such a high EPA concentration in liquid form minimizing the saturated fats; design, as it has liquid form; and solution, as the mentioned features constitute a solution for people having an extra requirement of fatty acids.

Goal in phase I is to develop a feasibility study, including a business plan which will cover all aspects of commercialization of LIFEOMEGA: technical, economical, risk assessment, IP, regulatory, bottle necks, market study, partner search, among others.

LIFEOMEGA has a great potential, as it is estimated that cancer patients receiving chemotherapy unfortunately won’t be less than 1 million/year during the next 11 years, in USA, Spain, France, Germany, UK and Italy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIFEOMEGA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIFEOMEGA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.3.2.)

EECHYMA (2015)

Eco-efficient high-yield production of antioxidant compounds from microalgae

Read More  

HEALTHSTOCK (2015)

Fodder for for HEALTHier animals and improved liveSTOCK production

Read More  

SCHOCKO3 (2015)

Novel Ozone and Thermal Shock Conservation Process for Vegetables

Read More